SCHEMBL5408548

SCHEMBL5408548

CCCCCc1c2ccccc2cc2sc3ccccc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.43
CNR1 P21554 2/20 0.43
MAPT P10636 2/20 0.42
MCL1 Q07820 1/20 0.38
NCEH1 Q6PIU2 1/20 0.38
TLR8 Q9NR97 6/20 0.37
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
PTPN1 P18031 1/20 0.36
GPR3 P46089 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15853291 0.86 MAPT (0.45) CNR2CNR1MAPTNCEH1TLR8
SCHEMBL23775992 0.83 GPR3 (0.42) CNR2CNR1MAPTNCEH1TSHR
SCHEMBL5502423 0.80 CNR2 (0.35) CNR2CNR1MAPTTLR8KDM4E
SCHEMBL2009887 0.80 CNR2 (0.39) CNR2CNR1MAPTMCL1KDM4E
SCHEMBL299862 0.78 MAPT (0.53) MAPTNCEH1TLR8KDM4EHSD17B10
SCHEMBL10058007 0.77 L3MBTL1 (0.39) CNR2CNR1MAPTTLR8KDM4E
SCHEMBL10058033 0.77 L3MBTL1 (0.39) CNR2CNR1MAPTTLR8KDM4E
SCHEMBL27804756 0.77 LIPG (0.40) CNR2CNR1MAPTTLR8KDM4E
SCHEMBL16267023 0.76 MAPT (0.55) MAPTTLR8KDM4EHSD17B10ALDH1A1
SCHEMBL5116260 0.76 MAPT (0.55) MAPTTLR8KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373605-B1 COMPOUNDS FOR USE IN THE TREATMENT OF PAIN UNIV DUNDEE (GB) 2014-08-13 EP disclosed
WO-2007028145-A2 AGENTS AND METHODS FOR REDUCING PROTEIN TYROSINE PHOSPHATASE 1B ACTIVITY IN THE CENTRAL NERVOUS SYSTEM DARA BIOSCIENCES, INC. (US) 2007-03-08 WO disclosed
US-7163952-B2 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2007-01-16 US disclosed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed
US-20050065196-A1 Azole compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-03-24 US disclosed
EP-1452530-A1 AZOLE COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-09-01 EP disclosed
US-6498182-B2 BENZO(G)INDOLE -2,5(3H)-DIONE AND -2-ONE DERIVATIVE ANTIDIABETIC AGENTS BIOVITRUM AB (SE) 2002-12-24 US disclosed
US-20020115663-A1 Novel compounds BIOVITRUM AB (SE) 2002-08-22 US disclosed
US-20020061921-A1 Novel compounds BIOVITRUM AB (SE) 2002-05-23 US disclosed
WO-2002026707-A1 NOVEL COMPOUNDS BIOVITRUM AB (SE) 2002-04-04 WO disclosed
WO-2002026743-A1 NOVEL PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF DIABETES BIOVITRUM AB (SE) 2002-04-04 WO disclosed
EP-1077970-A1 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
US-6110962-A FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 CNR2 428/4885CNR1 239/4885MAPT 4785/4885
US-20020115663-A1 Novel compounds SLC5A2, SLC5A1, GPR119 CNR2 81/4885CNR1 185/4885MAPT 3157/4885
US-20050065196-A1 Azole compound and medicinal use thereof PTPN7, PTPN1, PTPN5 CNR2 384/4885CNR1 185/4885MAPT 4536/4885
US-20020061921-A1 Novel compounds GPR119, IAPP, GLP1R CNR2 657/4885CNR1 575/4885MAPT 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.